Translate page

This Virtual Education Program, provided by the iCMLf offers a series of webcast presentations from leading hematologists.

These presentations provide updated information on treatment advances and best practice management of CML, including disease monitoring and new therapies. The sessions specifically address issues of CML care in countries with limited access to monitoring and supplemental treatments.

 

-- Virtual Education Program: 2019 Edition

 

Presentations from the COLT Meeting 2019

We are pleased to make available a series of presentations from the COLT Meeting 2019, a CML Opinion Leader Training that took place in Adelaide (Australia). Topics cover; CML therapy - state of science, management of CML, practicalities and monitoring TFR and Ph+ALL.


Timothy Hughes

David Yeung 3 Devendra Hiwase

Session 1: CML therapy - state of science
Chair: Prof. Tim Hughes

  • Frontline Therapy for CML 
    (Prof Tim Hughes)
  • When frontline therapy fails
    (Dr David Yeung)
  • CML - Beyond chronic phase
    (Dr Devendra Hiwase)

 

 

Naranie

David Yeung 3 Susan Branford                    

Session 2: CML Management, Practicalities
Chair: Dr David Yeung

  • Managing TKI toxicities
    (Dr Naranie Shanmuganathan)
  • Allograft - still a role in CML?
    (Dr David Yeung)
  • Molecular monitoring
    (A/Prof Susan Branford)

 

 

Susan Branford

 

David Yeung 3                  

 

Session 3: Monitoring TFR and Ph+ ALL
Chair: Dr Naranie Shanmunagathan

  • Monitoring TFR - Challenges 
    (A/Prof Susan Branford)
  • Ph+ ALL
    (Dr David Yeung)

 

Presentations from the 24rd Congress of EHA 

We are pleased to make available a couple of presentations on various aspects of CML management that were first presented at the 24rd Congress of the European Hematology Association in Amsterdam. Presentations include; CML treatment in the era of operational cure: considerations for therapy selection; current treatment approaches in CML, The future of CML therapy: unmet medical needs and new treatments in development, TKI safety and special aspects in children. 

 

Saglio EHA 2019 CML Treatment in the Era of Operational Cure: Considerations for Therapy Selection
Professor Giuseppe Saglio, University of Turin, Italy
 
  • Clinical case: Women, 39 years old including;
    • Considerations for prognosis
    • Considerations on the possibility of TFR
  • ENESTnd study - 5 year update including cumulative incidence of MR4.5
  • Nilotinib is the only TKI registered for discontinuation
  • Summary of Steering Group recommendations derived from patient-physician discussion
  • Conclusion 

This talk was first presented at EHA during the Satellite Symposium: 'Optimizing patient outcomes in CML and classical MPN's: New treatment paradigms and future developments' - supported by Incyte. You will find more education materials from EHA at the EHA Learning Centre